A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

BACKGROUND: This was an open-label, multicenter, single-arm phase Ib dose-escalation study of oral LCL161 administered in combination with oral topotecan in patients with relapsed/refractory small cell lung cancer (SCLC) and select gynecological cancers. METHODS: Cohorts of 3-6 patients initiated tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Melissa L, Patel, Manish R, Aljumaily, Raid, Jones, Suzanne F, Burris, III, Howard A, Spigel, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322128/
https://www.ncbi.nlm.nih.gov/pubmed/37129455
http://dx.doi.org/10.1093/oncolo/oyad029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322128/
https://www.ncbi.nlm.nih.gov/pubmed/37129455
http://dx.doi.org/10.1093/oncolo/oyad029

Ejemplares similares